Oscar Health raises FY26 earnings guidance by $100 million
- Oscar Health raised FY26 earnings from operations guidance by $100 million to $600-$800 million
- Medical loss ratio outlook tightened by 50 bps to 81.0%-82.0%
- Barclays raised price target to $49; Baird and Stephens also hiked targets
- Shares rose 2.38% to $33.11, approaching 52-week high of $34.47
- Total revenue guidance reaffirmed at $18.7-$19.0 billion
*this image is generated using AI for illustrative purposes only.
Oscar Health Inc (NYSE: OSCR) raised its full-year 2026 earnings from operations guidance by $100 million, prompting Wall Street analysts to hike price targets and driving shares up 2.38% to $33.11 on Thursday.
The health insurance company also upgraded its medical loss ratio (MLR) outlook, reflecting tighter cost controls on claims relative to premium revenue. The positive market reaction followed the company’s September Investor Day presentation and subsequent sell-side research updates.
Updated Financial Outlook
The insurer revised its key financial metrics for the full year ending December 31, 2026, as follows:
| Metric | Previous Guidance | Updated Guidance | Change |
|---|---|---|---|
| Earnings from Operations | $500 million – $700 million | $600 million – $800 million | +$100 million |
| Medical Loss Ratio | 81.5% – 82.5% | 81.0% – 82.0% | -50 bps |
| Total Revenue | $18.7 billion – $19.0 billion | $18.7 billion – $19.0 billion | Reaffirmed |
| SG&A Expense Ratio | 15.6% – 16.1% | 15.6% – 16.1% | Reaffirmed |
What the Numbers Show
The simultaneous improvement in earnings guidance and medical loss ratio indicates operational leverage rather than top-line growth. With total revenue guidance remaining flat at $18.7 billion to $19.0 billion, the $100 million increase in operating earnings is driven entirely by a reduction in claims costs. The 50 basis point tightening in the MLR range suggests Oscar expects to retain more of each premium dollar as underwriting profit, while maintaining administrative efficiency within the reaffirmed SG&A ratio of 15.6% to 16.1%.
Analyst Price Target Hikes
Several Wall Street firms updated their outlooks following the Investor Day:
- Barclays maintained an Overweight rating and raised its price target to $49.
- Baird maintained a Neutral rating but raised its price target to $33.
- Stephens & Co. reiterated an Equal-Weight rating with a $34 price target.
The stock is approaching its 52-week high of $34.47, according to Benzinga Pro data.
Investor Day Details
Oscar Health hosted its 2026 Investor Day on Wednesday, September 16, 2026, starting at 9:00 am Eastern Time. The event covered the company’s long-term strategy and financial targets. A live webcast and presentation materials were available on the company’s investor relations website.
How sustainable is Oscar Health's 50-basis point improvement in medical loss ratio given potential inflationary pressures on healthcare costs in 2027?
What specific operational strategies or technology implementations are driving the reduction in claims costs without impacting total revenue growth?
Will Oscar Health's improved underwriting profitability attract increased competition from traditional insurers, potentially squeezing future margins?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
